# INVO Fertility expands telehealth services at Wisconsin clinic

MIDDLETON, Wis. - INVO Fertility, Inc. (Nasdaq: IVF), a micro-cap fertility services provider currently valued at $2.7 million, announced Wednesday the expansion of telehealth capabilities at its Wisconsin Fertility Institute center to increase access to fertility care services.

Dr. Gretchen Collins, medical director at Wisconsin Fertility Institute, has obtained additional licenses in nine states: Illinois, Minnesota, Iowa, Montana, Colorado, Georgia, Alabama, Kansas, and Indiana. This licensing expansion enables the clinic to offer virtual consultations to patients across these states. According to InvestingPro data, this expansion comes as the company faces significant financial challenges, with its stock down nearly 90% over the past year.

The telehealth platform will provide remote access to initial consultations, follow-up visits, and cycle monitoring discussions. According to the company, all egg retrievals and embryo transfers will continue to be performed at the Wisconsin clinic’s physical location.

Steve Shum, CEO at INVO Fertility, stated that the telehealth integration aims to "break down geographic barriers" for fertility care.

The company indicated the service expansion is particularly targeted at individuals in rural or underserved areas who face challenges accessing specialized fertility treatment.

INVO Fertility operates two INVO Centers and one in vitro fertilization (IVF) clinic in the United States. The company also distributes its proprietary INVOcell medical device to third-party fertility clinics.

The announcement was made in a press release issued by the company.

In other recent news, INVO Fertility, Inc. has announced a definitive agreement with an institutional investor, involving an inducement letter to modify existing warrants. These warrants, initially issued earlier this year, will now be exercised for cash at a reduced price of $1.61 per share, with the company issuing new warrants for additional shares. This transaction is expected to generate approximately $750,000 in gross proceeds for INVO Fertility. Meanwhile, the company faces a potential delisting from the Nasdaq Stock Market for failing to file its Annual Report on time, although it plans to address this issue promptly. Additionally, the company has undergone a name change from NAYA Biosciences, Inc. to INVO Fertility, Inc., with plans to update its trading symbol soon. At a recent annual meeting, shareholders elected five directors and ratified the appointment of M&K CPAs PLLC as the independent public accountant. These developments reflect the company’s ongoing efforts to manage its financial and operational strategies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.